Glyco-poly-L-lysine is better than liposomal delivery of exogenous genes to rat of liver

Figure 1 Determination of the optimal proportion of liposome bound to plasmid by 1% agarose electrophoresis. Lane 1-8 are respectively 1-8 μL lipofectamine mixed with 1 μg pTM/MMP-1 plasmid. Plasmid 1 μg could only be encapsulated complet ely by more than 5 μL lipofectamine.

Figure 2 Determination of the optimal proportion of G-PLL bound to plasmid by 1% agarose electrophoresis. Lane 1-8 are respectively 0.05 μg, 0.1 μg, 0.2 μg, 0.3 μg , 0.4 μg, 0.5 μg, 1.0 μg, and 1.5 μg G-PLL mixed with 1 μg pTM/ MMP-1 plasmid. Plasmid 1 μg could only been bound completely by more than 0.4 μg G-PLL.

Figure 3 Immunostaining of flag-domain tag in the liver of rat 24 h after the admini stration of the plasmid bound to G-PLL (galactose-terminal glyco-poly-L-lysine) via cauda vein. × 200

Figure 4 In situ hybridization with biotin labeled oligonucleotide probe in the liver 3 wk after the administration of the plasmid encapsulated by liposome (lipofectamine) via cauda vein. × 100

Figure 5 The distribution and expression of the plasmid bound to liposomes or G-PLL (gal actose-terminal glyco-poly-L-lysine) in different tissues and at differe nt time points. A: liver, B: spleen, C: lung, D: kidney. LI: plasmid encapsulate d by liposomes given through cauda vein, PI: plasmid bound to G-PLL introduced intravenously.